In addition to a lower prevalence of STAG2 mutations as established by the multivariable analysis, low-risk patients were characterized by younger age (mean age: 4.6 years in low-risk patients vs. 16.1 years in high-risk patients), smaller tumor volumes (proportion of evaluable tumors with volume ≥ 200 mL: 2/15 [13.3%] in low-risk patients vs. 11/26 [42.3%] in high-risk patients), and a higher proportion of extraosseous tumors (11/18 [61.1%] vs. 2/31 [6.5%]). This evidence concerns the gene STAG2 and neoplasm.